🔎 Trials Near Me

Home › Cancer (all types) › NCT07327489

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

RecruitingObservational study

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

1. Able and willing to provide informed consent for participation
2. Age ≥18 years at time of consent.
3. Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy.
4. Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.

Exclusion Criteria:

1. Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment.
2. Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients.
3. Pregnant person(s).

About the study

This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.

What is being tested

Sponsor: Elephas · Participants: 2,000 · Started: Apr 14, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07327489

Locations in the U.S.

ArkansasMercy Hospital - FTS, Fort Smith
MarylandFrederick Health Hospital, Frederick
MissouriMercy Hospital - SPG, Springfield
Mercy Hospital - South, St Louis
Mercy Hospital -STL, St Louis
OklahomaMercy Hospital - OKC, Oklahoma City
TexasJPS Health Network, Forth Worth
Baylor Scott and White Biorepository, Temple (Not yet recruiting)

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.